Entropy Neurodynamics

Entropy Neurodynamics delivered a milestone quarter: TRP-8803 achieved 50% remission and 100% clinically meaningful response in Phase 2 BED Cohort 1. Cohort 2 is fully recruited, with topline data due Q4 CY2026. Read more: cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

Entropy Neurodynamics delivered a milestone quarter: TRP-8803 achieved 50% remission and 100% clinically meaningful response in Phase 2 BED Cohort 1. Cohort 2 is fully recruited, with topline data due Q4 CY2026. Read more: cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

🧠 Entropy Neurodynamics $ENP has secured a South African patent covering psilocybin and psilocin-based treatments for #fibromyalgia. The patent strengthens the Company's global IP portfolio and provides protection until September 2043. cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

🧠 Entropy Neurodynamics $ENP has secured a South African patent covering psilocybin and psilocin-based treatments for #fibromyalgia. The patent strengthens the Company's global IP portfolio and provides protection until September 2043. cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

ICYMI: $ENP has secured an Australian patent protecting proprietary psilocin crystalline forms until Sept 2043. The patent strengthens ENP's IP portfolio with composition-of-matter protection covering novel salt and cocrystal forms. cdn-api.markitdigital.com/apiman-gateway… #Biotech

🧬 $ENP has secured an Australian patent protecting proprietary psilocin crystalline forms until Sept 2043. The patent strengthens ENP's IP portfolio with composition-of-matter protection covering novel salt and cocrystal forms. cdn-api.markitdigital.com/apiman-gateway… #Biotech

Join Entropy Neurodynamics (#ASX: $ENP) for an Investor Webinar at 11:00am AEST (9:00am AWST) on Thursday, 9 July. CEO Jason Carroll will discuss the Phase 2 TRP-8803 results in treatment-resistant BED, followed by a live Q&A. Register: us02web.zoom.us/webinar/regist… #biotech

$ENP achieved world-first clinical efficacy results for precision-controlled IV #psilocin in treatment-resistant BED, with 50% complete remission, 100% clinically meaningful improvement and a 74% reduction in binge eating episodes. cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

From the @InvestorStream_ desk: 📢@Entropy_Neuro $ENP reports world-first clinical efficacy data for precision-controlled IV #psilocin ⚡Cohort 1 delivered 50% remission, 100% clinically meaningful improvement & a 74% reduction in binge eating episodes 🧠Cohort 2 fully enrolled

$ENP achieved world-first clinical efficacy results for precision-controlled IV #psilocin in treatment-resistant BED, with 50% complete remission, 100% clinically meaningful improvement and a 74% reduction in binge eating episodes. cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

$ENP advises the independent DSMB recommended progression of TRP-8803 Phase 2 BED trial to Cohort 2 w/ no protocol changes, confirming favourable safety & tolerability profile in Cohort 1 & supporting continued program development. Read more: cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

$ENP advises the independent DSMB recommended progression of TRP-8803 Phase 2 BED trial to Cohort 2 w/ no protocol changes, confirming favourable safety & tolerability profile in Cohort 1 & supporting continued program development. Read more: cdn-api.markitdigital.com/apiman-gateway… #ASX #Biotech

TRP-8802 validated the opportunity in treatment-resistant #IBS. The next question is whether $ENP ’s proprietary IV-infused #psilocin therapy can unlock even greater consistency, control and scalability. Dr Erin Mauney explains. youtu.be/KAnfXq8mdmE #biotech

TRP-8802 helped validate #IBS indication & gut-brain mechanism. @InvestorStream_ asked Dr Erin Mauney how $ENP ’s proprietary IV-infused psilocin therapy, TRP-8803, could build on findings & potentially deliver even more consistent treatment experience. youtu.be/KAnfXq8mdmE

As #psychedelic therapies continue to evolve, understanding how and why they work is becoming just as important as clinical outcomes. Dr Erin Mauney explains what latest #IBS data reveals about the gut-brain axis and future treatment opportunities. youtu.be/KAnfXq8mdmE $ENP

One of the most important findings from $ENP’s Phase 2a #IBS study wasn't just the response rate. It was the evidence supporting a potential underlying mechanism of action through the gut-brain axis. youtu.be/KAnfXq8mdmE #biotech #ASX

Q: ⁠Could the key to treating #IBS lie beyond the gut itself? Dr Erin Mauney discusses how the study's mechanistic findings are helping researchers better understand the role of the gut-brain axis in IBS. youtu.be/KAnfXq8mdmE $ENP #biotech

Q: The Phase 2a IBS study delivered more than strong efficacy data. Researchers also observed a link between symptom improvement & changes in key psychological measures, providing further support for the gut-brain axis hypothesis. youtu.be/KAnfXq8mdmE $ENP

Following the presentation of $ENP's Phase 2a #IBS results, Principal Investigator Dr Erin Mauney discusses the clinical outcomes, the gut-brain connection and why the study's findings could represent an important step forward in treatment-resistant IBS. youtu.be/KAnfXq8mdmE

Q: What happens when therapy delivers meaningful improvements in patients who've failed multiple treatment options? Dr Erin Mauney breaks down the clinical insights behind $ENP's TRP-8802 IBS data & what it could mean for millions living w/ #IBS. youtu.be/KAnfXq8mdmE